↑ 4.04.1Laine J, Künstle G, Obata T, Noguchi M (February 2002). "Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family". J. Biol. Chem. 277 (5): 3743–51. doi:10.1074/jbc.M107069200. PMID11707444.
↑French SW, Shen RR, Koh PJ, Malone CS, Mallick P, Teitell MA (May 2002). "A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane". Biochemistry. 41 (20): 6376–82. doi:10.1021/bi016068o. PMID12009899.
Further reading
Pekarsky Y, Hallas C, Croce CM (2001). "The role of TCL1 in human T-cell leukemia". Oncogene. 20 (40): 5638–43. doi:10.1038/sj.onc.1204596. PMID11607815.
Pekarsky Y, Zanesi N, Aqeilan R, Croce CM (2004). "Tcl1 as a model for lymphomagenesis". Hematol. Oncol. Clin. North Am. 18 (4): 863–79, ix. doi:10.1016/j.hoc.2004.04.007. PMID15325703.
Noguchi M, Ropars V, Roumestand C, Suizu F (2007). "Proto-oncogene TCL1: more than just a coactivator for Akt". FASEB J. 21 (10): 2273–84. doi:10.1096/fj.06-7684com. PMID17360849.
Fu TB, Virgilio L, Narducci MG, Facchiano A, Russo G, Croce CM (1995). "Characterization and localization of the TCL-1 oncogene product". Cancer Res. 54 (24): 6297–301. PMID7987816.
Hoh F, Yang YS, Guignard L, Padilla A, Stern MH, Lhoste JM, van Tilbeurgh H (1998). "Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology". Structure. 6 (2): 147–55. doi:10.1016/S0969-2126(98)00017-3. PMID9519406.
Takizawa J, Suzuki R, Kuroda H, Utsunomiya A, Kagami Y, Joh T, Aizawa Y, Ueda R, Seto M (1998). "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia". Jpn. J. Cancer Res. 89 (7): 712–8. doi:10.1111/j.1349-7006.1998.tb03275.x. PMID9738977.
Laine J, Künstle G, Obata T, Sha M, Noguchi M (2000). "The protooncogene TCL1 is an Akt kinase coactivator". Mol. Cell. 6 (2): 395–407. doi:10.1016/S1097-2765(00)00039-3. PMID10983986.
Laine J, Künstle G, Obata T, Noguchi M (2002). "Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family". J. Biol. Chem. 277 (5): 3743–51. doi:10.1074/jbc.M107069200. PMID11707444.
French SW, Shen RR, Koh PJ, Malone CS, Mallick P, Teitell MA (2002). "A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane". Biochemistry. 41 (20): 6376–82. doi:10.1021/bi016068o. PMID12009899.
Fears S, Chakrabarti SR, Nucifora G, Rowley JD (2002). "Differential expression of TCL1 during pre-B-cell acute lymphoblastic leukemia progression". Cancer Genet. Cytogenet. 135 (2): 110–9. doi:10.1016/S0165-4608(01)00655-0. PMID12127395.
French SW, Malone CS, Shen RR, Renard M, Henson SE, Miner MD, Wall R, Teitell MA (2003). "Sp1 transactivation of the TCL1 oncogene". J. Biol. Chem. 278 (2): 948–55. doi:10.1074/jbc.M207166200. PMID12421830.
Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2004). "TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin". Blood. 101 (12): 5007–9. doi:10.1182/blood-2002-10-3297. PMID12576313.